The Australian Medical Association (AMA) has highlighted the risk of expanding pharmaceutical prescribing rights to non-medical professionals as superbugs and the ‘silent pandemic’ of

Dr David Squirrell, a consultant ophthalmologist, passed away on 10 November 2025 after an accident in Queensland.

The first participant has been dosed in Opus Genetics OPGx-BEST1 Phase 1/2 clinical trial for Best disease (BEST1).

Heidelberg Engineering is joining the Collaborative Community on Ophthalmic Innovation (CCOI) – a public–private forum that convenes patients, clinicians, researchers, regulators, industry, and payors